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ABSTRACT 
 Atherosclerosis is a cardiovascular disease that is characterized by the hardening of 
arteries through the formation of cholesterol plaques. Cyclodextrins could potentially treat 
atherosclerosis by shrinking plaques. These cyclic oligosaccharides can make complexes 
with cholesterol but have also shown toxic side effects. This study looked for potential 
negative effects of cyclodextrins and cholesterol on gut bacteria. It was hypothesized that 
Bacteroides vulgatus will have decreased growth when grown in broth with cholesterol. In 
contrast, Clostridium bolteae will have decreased growth when grown in broth with 
cyclodextrins. Due to the fact that these bacteria are anaerobic, Clostridium bolteae and 
Bacteroides vulgatus, were grown using GAM broth under CO2. Data was collected by 
using a spectrophotometer to measure changes in bacterial growth throughout the growth 
cycle. Each bacteria was treated with one of three chemicals at one of three concentration 
to make a total of 9 different conditions. α-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin, 
and cholesterol with concentrations of 1 mM, 10 mM, and 100 mM. The slopes of the log 
phase of bacterial growth were compared using a two tailed T-Test with α=0.05. Growth 
of Clostridium bolteae was significantly inhibited for most of the cyclodextrin trials and 
all the cholesterol concentrations. Bacteroides vulgatus growth was inhibited by 100 mM 
concentrations of cholesterol and α-cyclodextrins. Interestingly, Bacteroides vulgatus 
growth was significantly increased when grown with 1 mM and 10 mM concentrations of 
cholesterol. Continued research is needed to determine when cholesterol concentrations 
become harmful to Bacteroides vulgatus. Clostridium bolteae needs further research to 
understand the 10 mM α-cyclodextrin trial that did not show significant inhibition. The 
results demonstrate that cyclodextrins are associated with inhibited growth for these two 
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gut bacteria but expansion of this test to other gut bacteria is key for a deeper understanding 
of the impact that cyclodextrins would have on the gut microbiome as a whole. 
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INTRODUCTION 
Atherosclerosis is a cardiovascular disease that has one of the highest mortality 
rates in the world. It is characterized by the formation of cholesterol-filled plaques that 
are chronically inflamed and continue to develop until they occlude the artery or break 
off causing a stroke or heart attack. Statins are the current standard treatment for 
atherosclerosis and for the precursor to atherosclerosis, high cholesterol. These drugs 
lower the levels of unhealthy lipoproteins to slow the progression of plaques (Lusis 
2000). However, there remains a gap in medical treatment for a way to reduce 
inflammation and remove cholesterol from plaques to lower the risk for heart attacks and 
strokes. Cyclodextrins are oligosaccharides that have been found to regress 
atherosclerosis by decreasing inflammation and shrinking plaques (Zimmer et al. 2016). 
Cyclodextrins are known to extract cholesterol from membranes. The possible 
mechanism for this removal was shown using a computer simulation; it demonstrated that 
cyclodextrins form dimers to pull out cholesterol molecules, forming 2:1 cyclodextrin-
cholesterol complexes (LóPez et al. 2011). Cholesterol is key to the structural integrity of 
cell membranes; it is possible that cyclodextrins are causing changes in cell membranes 
of gut bacteria that is impacting their growth. The present study was designed to test the 
impact of cyclodextrins on the growth of gut bacteria. 
2-Hydroxypropyl-β-cyclodextrin (HPβCD) has been shown to solubilize 
cholesterol and have minimal cytotoxic effects on human cells (Szente et al. 2018). 
HPβCD is being studied in clinical trials for the treatment of Niemann-Pick C, a fatal 
hereditary disease that can be characterized by the buildup of cholesterol in lysosomes 
(Singhal et al. 2018). HPβCD promotes the removal of cholesterol from these lysosomes 
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through a similar mechanism to atherosclerotic plaque regression. HPβCD is a 
frontrunner in atherosclerosis research because of its success in Niemann-Pick C clinical 
trials (Singhal et al. 2018). Another commonly studied cyclodextrin for atherosclerosis 
treatment is α-cyclodextrin (αCD). αCD was found to inhibit inflammatory pathways 
better than HPβCD (Pilely et al. 2019). In one study, αCD was also found to decrease 
obesity by improving lipid metabolism in mice. Interestingly, these mice were fed high 
fat diets which negatively affected their gut microbiome; then other mice were fed the 
same diet with αCD and had another large change in bacterial composition as shown in 
the graph below. There was a decrease in the Bacteroides genus in mice fed a high fat 
diet (HFD) but they rebounded in mice that were treated with αCD along with their HFD. 
On the other hand, Clostridium cluster XIVa was increased in mice that were fed a HFD 
but drastically decreased when αCD was added.  
 
Figure 1. This graph depicts the change in gut bacteria population in mice. The three columns compare 
mice fed a normal diet (ND), mice fed a high fat diet (HFD) and mice fed a HFD and treated with αCD 
(Nihei et al. 2018). 
These results raise the following questions: what exactly is impacting the growth 
of these bacteria? Is it the high cholesterol levels, introduction of cyclodextrin or both? 
Cyclodextrins are not absorbed so they must be fermented by the gut bacteria. This 
means there is direct contact between the bacteria and these molecules (Amar et al. 
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2016). A study done of human erythrocytes and a Caco-2 cell line showed that αCD was 
cytotoxic to these cells; however, once a complex was formed with cholesterol the 
cytotoxicity of αCD decreased. This same study proposed that αCD could also form 
complexes with phospholipids (Roka et al. 2015). The mechanism for cyclodextrin 
cytotoxicity has not been confirmed but is speculated to be related to the removal of 
cholesterol from membranes and potentially removal of phospholipids as well, which 
could be dangerous for the bacteria of the human microbiome. This goal of the 
experiment is to observe any major cytotoxic effects that cyclodextrins may have on 
human gut bacteria and test the theorized protective qualities of the cyclodextrin-
cholesterol complexes.  
The human microbiome has become the focus of research for a variety of diseases 
because of its connectivity to human health. Atherosclerosis is no exception; distinct 
changes in the human gut microbiome have been noted in patients with atherosclerosis 
(Jie et al. 2017). Analysis of these changes of bacteria found that inflammation increased 
when certain strains of bacteria were decreased in vivo (Yoshida, Naofumi Emoto, Takuo 
Yamashita 2018). Clostridium bolteae  and Bacteroides vulgatus are anaerobic bacteria 
found in the human gut microbiome (Maier et al. 2018). Each has their own unique 
properties and benefits for overall health. B. vulgatus was studied specifically in mice 
with induced atherosclerosis and was found to have anti-inflammatory effects (Yoshida, 
Naofumi Emoto, Takuo Yamashita 2018). This is an important piece of information 
because the genus, Bacteroides, was found to be less prevalent in the gut of mice that 
were fed a high fat diet. On the other hand, C. bolteae is a member of Clostridium cluster 
XIVa which was found to be increased in mice being fed a high fat diet (Nihei et al. 
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2018). These changes can be seen in the figure above. Clostridium bacteria have been 
found to both be proinflammatory and to help regulate inflammation depending on the 
species (Barnes and Powrie 2011). A healthy balance of gut bacteria is key to a healthy 
host. It is vitally important to be aware of how different treatments affect microbiome 
health to ensure that they are as beneficial as possible and do not have unforeseen side 
effects. Cyclodextrins could be damaging these bacterial membranes by removing 
cholesterol from them, or through a different mechanism, but either way it is important to 
see if these bacteria are being negatively affected by cyclodextrin treatment. The human 
microbiome plays an important role in atherosclerosis so the health of these bacteria is 
vital and should be considered when testing possible treatments.  
Despite the promising data suggesting that cyclodextrins may help to regress 
atherosclerotic plaques, the specific, direct effects of cyclodextrins on the gut bacteria B. 
vulgatus and C. bolteae are not clear. In vivo studies are plagued by complex variables 
that are difficult to control. Isolating individual bacteria for testing can negate these 
variables.  B. vulgatus was decreased in both human and mouse studies when under 
atherosclerotic conditions, while C. bolteae was decreased when αCD was introduced 
into the diet of the mice. This leads to the central questions being addressed in this 
current proposal: what are the effects of cyclodextrins on these bacterial strains, and does 
co-treatment with cholesterol change those effects?  Cholesterol and cyclodextrins form 
complexes with a dimer of cyclodextrins pulling a cholesterol molecule in and this 
complexation may combine the potentially harmful chemicals into a harmless complex. 
Based on the changes that occur in vivo the following hypotheses were developed:  
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1. Bacteroides vulgatus will have decreased growth when grown in broth with 
cholesterol. 2. Clostridium bolteae will have decreased growth when grown in broth with 
cyclodextrins.  
METHODS 
Materials 
Clostridium bolteae – ATCC 
Bacteroides vulgatus – ATCC 
αCD 98% (100g) – Fischer Scientific 
HPβCD mw ~ 1540 (100g) – Fischer Scientific 
Cholesterol 92.5% (25g) – Sigma Aldrich 
Gifu Anaerobic Broth (500g) – Thomas Scientific 
Falcon Tubes (12mL) 
Single use sterile pipets (1mL, 5mL & 10mL) 
Equipment 
UV/VIS spectrophotometer 
Shaking water bath incubator  
Carbon Dioxide gas tank 
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Methods 
Bacteroides vulgatus was revived from frozen stock in gifu anaerobic broth 
(GAM) in a shaking water incubator. Growth curves were determined using the same 
procedure for each trial: two bacterial falcon tubes were made containing 10 mL of fresh 
broth and 0.5 mL of bacteria containing broth. These tubes were made anaerobic by 
filling them with carbon dioxide gas then immediately sealing them. 1 mL samples were 
taken every hour, alternating between two tubes. Every time a tube was opened it was 
filled with carbon dioxide again. The absorbance of these samples were immediately 
measured at 560 nm using the UV/Vis spectrophotometer. The absorbance and time of 
each sample were recorded to create the growth curve. Untreated samples were tested 
every hour for 6 hours followed by two additional tests with two hour gap. This was 
found to accurately capture the growth curve of B. vulgatus and was used for the 
experimental trials as well. αCD, HPβCD, and cholesterol were all tested individually at 
three different concentrations: 1mM, 10mM and 100mM. Three trials were run for each 
treatment to limit random error. Combined trials were run for these four different 
concentrations: 100mM αCD +100mM cholesterol, 100mM αCD +50mM cholesterol, 
100mM HPβCD +100mM cholesterol, and 100mM HPβCD +50mM cholesterol. Each 
combination was run with two trials each.  
Clostridium bolteae was rehydrated from a freeze-dried stock in GAM broth in a shaking 
water bath then frozen stocks were made the same way as previously stated. All methods 
were the same for C. bolteae apart from the times that samples were taken. The 
absorbances were recorded at these times: 0.5hr, 1hr, 2hr, 2.5hr, 3hr, 4hr, 5hr, 6hr.  
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Growth curves were by measuring the slope of the log phase growth where the linear 
upward slope was found. The slopes of each trial were compared to the slopes of the 
control with a two-tailed T-test. The data is displayed as means +/- standard deviation 
and P values of less than 0.05 will be used as the threshold for determining statistical 
significance. 
RESULTS 
 Bacteroides vulgatus and Clostridium bolteae have nine different growth curves 
for the nine treatments. The standard growth curve follows a sigmoidal shape with a 
linear growth period. The slope of the linear growth was found using a line of best fit. 
The slopes were compared to a standard control slope. Figure 2 shows all three alpha 
cyclodextrin treatments for Bacteroides vulgatus along with a control curve. The right 
graph shows the curves after they have been cropped to only display the linear growth 
period. Of the three alpha cyclodextrin treatments on Bacteroides vulgatus only 100 mM 
was shown to significantly decrease growth.  
 
Figure 2. The effects of alpha cyclodextrin on Bacteroides vulgatus growth. These two graphs display the 
same set of data. The data displayed were from mean values with error bars showing 1 standard deviation. 
The second graph has been cropped to only display the linear segment of growth. The line of best fit was 
found for this segment then compared using a two-tailed T-test.  
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Bacteroides vulgatus had decreased growth with two treatments and two other 
treatments had increased growth. 1 mM and 10 mM cholesterol showed a significant 
increase in growth rate. 100 mM concentrations of cholesterol and αCD were shown to 
inhibit growth. Figure 3 depicts the growth curves for all four treatments along with a 
standard growth curve.  
 
 
Figure 3. These graphs are depicting all the results that were statistically significant for Bacteroides 
vulgatus. T-test was run with alpha = 0.05 to compare the slopes of the log phase.  
Clostridium bolteae had a statistically significant decrease in growth for eight of 
the nine treatments. All HPβCD and all cholesterol along with 1 mM and 100 mM αCD 
were shown to inhibit Clostridium bolteae growth. Theses eight treatment have a growth 
curve that is displayed in figure 4.  
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Figure 4. These graphs are depicting all the results that were statistically significant for Clostridium 
bolteae. T-test was run with alpha = 0.05 to compare the slopes of the log phase growth. All the 
concentrations shown were inhibiting growth. 
Table 1 includes all the mean slope values with one standard deviation along with 
their corresponding p values. The minimum significant p value is 0.05. There are twelve 
statistically significant treatments between both of the bacteria tested.  
Table 1. Results from Bacteroides vulgatus and Clostridium bolteae under varying conditions. Slopes from 
the log phase of graphs for each trial were analyzed by a two- tailed t-test, p values are shown below. There 
were varied levels of significance, values with p≤0.05 are marked with *, p≤0.01 is marked with **, and 
p≤0.001***. 
 
 
 
  Bacteroides vulgatus Clostridium bolteae 
Treatment Concentration Slope ± 1SD  T.TEST p value Slope ± 1SD  T.TEST p value 
Control 
 
0.0034 ± 0.00036 
 
0.0052 ± 0.0002  
 1mM 0.00353 ± 0.00029 0.6433 0.00403 ± 0.00058 0.02973* 
Alpha Cyclodextrin 10mM 0.00367 ± 0.000058 0.2746 0.0052 ± 0.00035 1 
 
100mM -0.000053 ± 0.000021 0.00007785*** -0.000087 ± 0.000058  0.000001363*** 
 1mM 0.0034 ± 0.0001 1 0.00423 ± 0.0004  0.0206* 
Beta Cyclodextrin 10mM 0.00357 ± 0.000058 0.4734 0.00413 ± 0.00042  0.01613*  
100mM 0.00303 ± 0.000058 0.157 0.00357 ± 0.00071  0.01849* 
Cholesterol 
1mM 0.00603 ± 0.00015 0.000311*** 0.00463 ± 0.00012  0.01316* 
10mM 0.0048 ± 0.00066 0.03166* 0.00353 ± 0.00029  0.001194**  
100mM -0.00022 ± 0.000144 0.00008642*** -0.00005 ± 0.00001  0.000001407*** 
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DISCUSSION 
 Bacteroides vulgatus was treated with nine different trials. Of those nine trials, 
four were statistically significant and this can be seen in table 1. Although five of the nine 
trials showed no significant change in growth, these are still important trials. 2-
hydroxypropyl-β-cyclodextrin is specifically designed to be less toxic, the added 
hydroxypropyl groups decrease the affinity for cholesterol which has been shown to 
lower the toxicity (Szente et al. 2018). The data for Bacteroides vulgatus is consistent 
with this purpose, even at 100 mM concentration the growth of this bacteria was not 
significantly inhibited. α-cyclodextrin is unsubstituted but this does not mean there are no 
toxic effects. On the contrary the toxic effects can be seen in the trial when Bacteroides 
vulgatus was treated with 100 mM α-cyclodextrin and it was significantly inhibited. This 
inhibition is not present at lower concentrations. This is consistent with the previous 
study that α-cyclodextrin is slightly more toxic than 2-hydroxypropyl-β-cyclodextrin but 
both are still being studied as treatments for atherosclerosis (Szente et al. 2018).  The 
hypothesis for Bacteroides vulgatus was that it would be inhibited when grown in broths 
with cholesterol. This was based on study by Jie et al. on patients with atherosclerosis 
where their gut microbiome was analyzed for consistent changes occurring in most 
atherosclerotic patients. The Bacteroides genus was decreased in general, and it was 
suspected that these bacteria grow poorly under high fat conditions that usually 
associated with atherosclerosis. This was supported by the study done by Nihei et al. on 
mice. Cholesterol was tested because of the limited ability to replicate a high fat diet in 
vitro. This hypothesis is supported at 100 mM cholesterol concentrations where 
Bacteroides vulgatus was significantly inhibited. Surprisingly, 1 mM and 10 mM 
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concentrations of cholesterol significantly increased the growth of Bacteroides vulgatus. 
There was more increased growth in the 1 mM than the 10 mM then at 100 mM the 
growth becomes inhibited. The mechanism for this increased growth in unknown. The 
data presented for the lower concentrations of cholesterol contradict the predicted trend. 
This may be to due to the fact that the studies were using high fat diets while this study 
looked at cholesterol alone (Jie et al. 2017; Nihei et al. 2018). There is more research to 
be done to see where the concentrations of cholesterol transitions from beneficial to 
harmful. There is also a need for this study to be replicated to see if similar results are 
being found. This is only one species in the Bacteroides genus and it would be beneficial 
to learn if the entire genus reacts similarly to these conditions. It is difficult to draw large 
conclusions based off a study on a specific bacteria when the gut microbiome is a diverse 
population. The diversity of the microbiome is key to its function and a possible 
unwanted side effect of cyclodextrins could be the destruction of that diversity. 
 Clostridium bolteae was treated with the same nine trials as Bacteroides vulgatus. 
This bacteria was more susceptible to inhibition; it was significantly inhibited by eight of 
the nine trials. Interestingly, the only trial that did not show any significant changes in 
growth was 10 mM α-cyclodextrin. All other data was consistent with previous studies. 
Similar to Bacteroides vulgatus, 100 mM concentrations of cholesterol and α-
cyclodextrin are inhibiting growth significantly. The slopes are nearly zero for these two 
trials as it is seen in table 1. The lower concentrations of α-cyclodextrin and cholesterol, 
with the exception of 10 mM α-cyclodextrin, make intuitive sense. The lower the 
concentration, the lower the significance in growth inhibition. 2-hydroxypropyl-β-
cyclodextrin is expected to be less toxic than α-cyclodextrin. In 1 mM concentrations the 
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two significance values are very similar and 10 mM concentrations are complicated. 
When comparing the 100 mM concentration the expected result can be clearly seen. 100 
mM α-cyclodextrin has a slope of nearly zero while 100 mM 2-hydroxypropyl-β-
cyclodextrin still shows growth. This is consistent with the idea presented earlier that 2-
hydroxypropyl-β-cyclodextrin is less toxic than α-cyclodextrin (Szente et al. 2018). The 
hypothesis for Clostridium bolteae was that there would be inhibited growth when grown 
in both with cyclodextrins. This is supported by results from a study on mice that were 
treated with cyclodextrins, and they had decreased Clostridium populations (Nihei et al. 
2018). In general, this is supported with the data from this study, except for 10 mM α-
cyclodextrin. It is key to note that Bacteroides vulgatus was unaffected by 2-
hydroxypropyl-β-cyclodextrin but Clostridium bolteae had significant growth inhibition 
at all concentrations. This supports that hypothesis that Clostridium bolteae is specifically 
inhibited by cyclodextrins even the one deemed safer than the others 2-hydroxypropyl-β-
cyclodextrin. Clostridium bolteae also showed significant growth inhibition for 
cholesterol at all concentrations. In Jie’s study on atherosclerotic patients the Clostridium 
genus was increased in these patients, unlike the Bacteroides genus. There is not research 
supporting the decreased growth of Clostridium bolteae in cholesterol. Bacteroides 
vulgatus is not entirely representative the Bacteroides genus but the Clostridium genus is 
even more varied (Barnes and Powrie 2011). There is a need for further research on other 
members of the Clostridium genus to explain the increase of the population under 
atherosclerotic conditions. There is a possibility that Clostridium bolteae decreases but 
other species thrive. This points to the importance of expanding the study to include a 
large variety of species of gut bacteria.  
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CONCLUSION 
The results from these two bacteria show that cyclodextrins can inhibit gut 
bacteria although further research should be done to see if this inhibition will be 
universally detrimental to the gut microbiome. The results indicate that there is some 
dose dependence on the inhibition. The health of gut microbiome composition should be 
monitored in future clinical research. Further research is needed to fully understand the 
general impact that cyclodextrins would have on the gut microbiome. This study was 
limited by the small number of bacteria tested along with limited concentration range. 
The maintenance of an anerobic environment was difficult to control and while it was 
every attempt was made to control the environment, oxygen contamination could 
contribute to the results. Overall, this research supports cyclodextrins having adverse side 
effects on gut bacteria while raising new questions for future work. 
 
  
14 
 
REFERENCES 
Amar MJA, Kaler M, Courville AB, Shamburek R, Sampson M, Remaley AT. 2016. 
Randomized double blind clinical trial on the effect of oral α-cyclodextrin on 
serum lipids. Lipids Health Dis. 15:115. doi:10.1186/s12944-016-0284-6. 
[accessed 2019 Sep 8]. 
http://lipidworld.biomedcentral.com/articles/10.1186/s12944-016-0284-6. 
Barnes MJ, Powrie F. 2011. The Gut’s Clostridium Cocktail. Science (80-. ). 331:289–
290. doi:10.1126/science.1201291. [accessed 2019 Sep 15]. 
www.sciencemag.orgSCIENCEVOL. 
Jie Z, Xia H, Zhong S-L, Feng Q, Li S, Liang S, Zhong H, Liu Z, Gao Y, Zhao H, et al. 
2017. The gut microbiome in atherosclerotic cardiovascular disease. Nat. 
Commun. 8:845. doi:10.1038/s41467-017-00900-1. [accessed 2019 Sep 8]. 
www.nature.com/naturecommunications. 
LóPez CA, De Vries AH, Marrink SJ. 2011. Molecular Mechanism of Cyclodextrin 
Mediated Cholesterol Extraction. PLoS Comput Biol 7:1002020. 
doi:10.1371/journal.pcbi.1002020. [accessed 2019 Sep 1]. 
www.ploscompbiol.org. 
Lusis AJ. 2000. Atherosclerosis. Nature 407:233–241. 
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Erin anderson E, rita Brochado A, 
conrad Fernandez K, Dose H, Mori H, et al. 2018. Extensive impact of non-
antibiotic drugs on human gut bacteria. Nature 555:623–627. 
doi:10.1038/nature25979. [accessed 2019 Sep 3]. 
15 
 
https://search.proquest.com/docview/2020725614/fulltextPDF/49F1ABBC2A084
BC9PQ/1?accountid=12974. 
Nihei N, Okamoto H, Furune T, Ikuta N, Sasaki K, Rimbach G, Yoshikawa Y, Terao K. 
2018. Research Communication Dietary a-cyclodextrin modifies gut microbiota 
and reduces fat accumulation in high-fat-diet-fed obese mice. Biofactors:336–347. 
doi:10.1002/biof.1429. [accessed 2019 Aug 29]. 
http://content.ebscohost.com/ContentServer.asp?T=P&P=AN&K=29733482&S=
R&D=mnh&EbscoContent=dGJyMNLe80SeqLc4v%2BvlOLCmr1GeqK5Sr6q4
SbaWxWXS&ContentCustomer=dGJyMPGuslC3rLZIuePfgeyx44Dt6fIA. 
Pilely K, Bakke SS, Palarasah Y, Skjoedt M-O, Bartels ED, Espevik T, Garred P. 2019. 
Alpha-cyclodextrin inhibits cholesterol crystal-induced complement-mediated 
inflammation: A potential new compound for treatment of atherosclerosis. 
Atherosclerosis 283:35–42. doi:10.1016/J.ATHEROSCLEROSIS.2019.01.034. 
[accessed 2019 Aug 26]. 
https://www.sciencedirect.com/science/article/pii/S0021915019300589. 
Singhal A, Szente L, Hildreth JEK, Song B. 2018. Hydroxypropyl-beta and -gamma 
cyclodextrins rescue cholesterol accumulation in Niemann–Pick C1 mutant cell 
via lysosome-associated membrane protein 1. Cell Death Dis. 9:1019. 
doi:10.1038/s41419-018-1056-1. [accessed 2019 Sep 8]. 
http://www.nature.com/articles/s41419-018-1056-1. 
Szente L, Singhal A, Domokos A, Song B. 2018. Cyclodextrins: Assessing the Impact of 
Cavity Size, Occupancy, and Substitutions on Cytotoxicity and Cholesterol 
16 
 
Homeostasis. Molecules 23:1–15. doi:10.3390/molecules23051228. [accessed 
2019 Aug 29]. www.mdpi.com/journal/molecules. 
Yoshida, Naofumi Emoto, Takuo Yamashita T. 2018. Bacteroides vulgatus and 
Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and 
Inhibit Atherosclerosis. Circulation 138:2486–2498. 
doi:10.1161/CIRCULATIONAHA.118.033714. [accessed 2019 Sep 15]. 
http://trace.ddbj.nig. 
Zimmer S, Grebe A, Bakke SS, Bode N, Halvorsen B, Ulas T, Skjelland M, De Nardo D, 
Labzin LI, Kerksiek A, et al. 2016. Cyclodextrin promotes atherosclerosis 
regression via macrophage reprogramming. Sci. Transl. Med. 8:333ra50. 
doi:10.1126/scitranslmed.aad6100. [accessed 2019 Aug 26]. 
http://www.ncbi.nlm.nih.gov/pubmed/27053774. 
 
 
